Oportuzumab monatox

From WikiMD.org
Jump to navigation Jump to search

Oportuzumab Monatox

Oportuzumab Monatox (pronunciation: oh-por-tuh-zoo-mab mon-a-tox) is a biologic therapy used in the treatment of non-muscle invasive bladder cancer (NMIBC). It is also known by its brand name, Vicinium.

Etymology

The name Oportuzumab Monatox is derived from the combination of two components: Oportuzumab, a monoclonal antibody that targets the protein EpCAM found on the surface of bladder cancer cells, and Monatox, a derivative of the Pseudomonas aeruginosa bacterial toxin.

Usage

Oportuzumab Monatox is used for the treatment of BCG-unresponsive, high-grade NMIBC in patients who have previously received a minimum of two courses of Bacillus Calmette-Guérin (BCG) and who are ineligible for or have elected not to undergo cystectomy.

Mechanism of Action

Oportuzumab Monatox works by binding to the EpCAM protein on the surface of bladder cancer cells. Once bound, the toxin component of the drug is internalized by the cancer cell, inhibiting protein synthesis and leading to cell death.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski